445 related articles for article (PubMed ID: 22552779)
1. Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.
Eckert GP; Renner K; Eckert SH; Eckmann J; Hagl S; Abdel-Kader RM; Kurz C; Leuner K; Muller WE
Mol Neurobiol; 2012 Aug; 46(1):136-50. PubMed ID: 22552779
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer's Disease.
Stockburger C; Eckert S; Eckert GP; Friedland K; Müller WE
J Alzheimers Dis; 2018; 64(s1):S455-S467. PubMed ID: 29504539
[TBL] [Abstract][Full Text] [Related]
3. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
[TBL] [Abstract][Full Text] [Related]
4. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions.
Kumar A; Singh A
Front Pharmacol; 2015; 6():206. PubMed ID: 26441662
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial permeability transition pore contributes to mitochondrial dysfunction in fibroblasts of patients with sporadic Alzheimer's disease.
Pérez MJ; Ponce DP; Aranguiz A; Behrens MI; Quintanilla RA
Redox Biol; 2018 Oct; 19():290-300. PubMed ID: 30199818
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium.
Singulani MP; De Paula VJR; Forlenza OV
Neurosci Lett; 2021 Aug; 760():136078. PubMed ID: 34161823
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction and Alzheimer's disease: prospects for therapeutic intervention.
Lim JW; Lee J; Pae AN
BMB Rep; 2020 Jan; 53(1):47-55. PubMed ID: 31818365
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction: A potential target for Alzheimer's disease intervention and treatment.
Ke J; Tian Q; Xu Q; Fu Z; Fu Q
Drug Discov Today; 2021 Aug; 26(8):1991-2002. PubMed ID: 33962036
[TBL] [Abstract][Full Text] [Related]
9. Prolong treatment with Trans-ferulic acid mitigates bioenergetics loss and restores mitochondrial dynamics in streptozotocin-induced sporadic dementia of Alzheimer's type.
Zafeer MF; Firdaus F; Anis E; Mobarak Hossain M
Neurotoxicology; 2019 Jul; 73():246-257. PubMed ID: 31029786
[TBL] [Abstract][Full Text] [Related]
10. Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer's neurons.
Guo L; Du H; Yan S; Wu X; McKhann GM; Chen JX; Yan SS
PLoS One; 2013; 8(1):e54914. PubMed ID: 23382999
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease.
Reddy PH; Manczak M; Yin X; Grady MC; Mitchell A; Kandimalla R; Kuruva CS
J Investig Med; 2016 Dec; 64(8):1220-1234. PubMed ID: 27521081
[TBL] [Abstract][Full Text] [Related]
12. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model.
Du H; Guo L; Yan S; Sosunov AA; McKhann GM; Yan SS
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18670-5. PubMed ID: 20937894
[TBL] [Abstract][Full Text] [Related]
13. Natural products as pharmacological modulators of mitochondrial dysfunctions for the treatments of Alzheimer's disease: A comprehensive review.
Jin X; Guo JL; Wang L; Zhong X; Yao WF; Gao H; Liu MY
Eur J Med Chem; 2021 Jun; 218():113401. PubMed ID: 33831779
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta.
Du H; Yan SS
Biochim Biophys Acta; 2010 Jan; 1802(1):198-204. PubMed ID: 19616093
[TBL] [Abstract][Full Text] [Related]
15. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities.
Carvalho C; Cardoso S; Correia SC; Santos RX; Santos MS; Baldeiras I; Oliveira CR; Moreira PI
Diabetes; 2012 May; 61(5):1234-42. PubMed ID: 22427376
[TBL] [Abstract][Full Text] [Related]
16. The obesity-related peptide leptin sensitizes cardiac mitochondria to calcium-induced permeability transition pore opening and apoptosis.
Martinez-Abundis E; Rajapurohitam V; Haist JV; Gan XT; Karmazyn M
PLoS One; 2012; 7(7):e41612. PubMed ID: 22848545
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?
Leuner K; Hauptmann S; Abdel-Kader R; Scherping I; Keil U; Strosznajder JB; Eckert A; Müller WE
Antioxid Redox Signal; 2007 Oct; 9(10):1659-75. PubMed ID: 17867931
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
19. Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes.
Leuner K; Schulz K; Schütt T; Pantel J; Prvulovic D; Rhein V; Savaskan E; Czech C; Eckert A; Müller WE
Mol Neurobiol; 2012 Aug; 46(1):194-204. PubMed ID: 22821186
[TBL] [Abstract][Full Text] [Related]
20. Grape seed proanthocyanidins ameliorate neuronal oxidative damage by inhibiting GSK-3β-dependent mitochondrial permeability transition pore opening in an experimental model of sporadic Alzheimer's disease.
Sun Q; Jia N; Li X; Yang J; Chen G
Aging (Albany NY); 2019 Jun; 11(12):4107-4124. PubMed ID: 31232699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
